以下是知识库中与该主题相关的实验方案、常见问题、指南与技术文章。
In the field of cancer research, the KRAS gene has always occupied an important and unique position. For many years, due to its complex structure and functional characteristics, KRAS has been regarded as an "undruggable" target.
在癌症研究领域，KRAS基因一直占据着重要且特殊的地位。多年来，由于其复杂的结构和功能特性，KRAS被视为 “不可成药” 靶点，然而随着科研技术的不断进步，针对KRAS的靶向治疗取得了突破性进展。
The KRAS G12C mutation is one of the common driver mutations in malignant tumors such as colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Recently approved KRAS G12C inhibitors like Adagrasib (MRTX849) and Sotorasib have provided unprecedented therapeutic options for patients.
KRAS G12C突变是结直肠癌（CRC）与非小细胞肺癌（NSCLC）等恶性肿瘤中常见的驱动突变之一。近年上市的KRAS G12C抑制剂如Adagrasib（MRTX849）和Sotorasib为患者提供了前所未有的治疗选择。
同一批资源中共同出现的其他主题。
危险品化学品经营许可证（带存储）